Search results for "double-blind method"

showing 10 items of 631 documents

The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics

2020

Abstract Background The Dapagliflozin and Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD; NCT03036150) trial was designed to assess the effect of the sodium–glucose co-transporter 2 (SGLT2) inhibitor dapagliflozin on kidney and cardiovascular events in participants with CKD with and without type 2 diabetes (T2D). This analysis reports the baseline characteristics of those recruited, comparing them with those enrolled in other trials. Methods In DAPA-CKD, 4304 participants with a urinary albumin:creatinine ratio (UACR) ≥200 mg/g and estimated glomerular filtration rate (eGFR) between 25 and 75 mL/min/1.73 m2 were randomized to dapagliflozin 10 mg once daily or placebo. Me…

MaleIGA NEPHROPATHYRATIONALEPROGRESSIONType 2 diabetesurologic and male genital diseasesDiabetic nephropathychemistry.chemical_compoundGlucosidesDESIGNMedicineFAILUREDiabetic NephropathiesDapagliflozinrandomized controlled clinical trialPrognosisfemale genital diseases and pregnancy complications//purl.org/pe-repo/ocde/ford#3.02.13 [https]Cardiovascular DiseasesNephrologyFemalesodium–glucose co-transporter-2 inhibitormedicine.symptomBENAZEPRILGlomerular Filtration Ratemedicine.medical_specialtyFinerenoneINHIBITIONNephropathy//purl.org/pe-repo/ocde/ford#3.02.20 [https]Double-Blind MethodClinical ResearchInternal medicineDiabetes mellitusEND-POINTSHumansBenzhydryl CompoundsRenal Insufficiency ChronicAcademicSubjects/MED00340Sodium-Glucose Transporter 2 InhibitorsAgedTransplantationDECLINEbusiness.industrysodium-glucose co-transporter-2 inhibitordapagliflozinmedicine.diseaseEFFICACYEditor's ChoiceDiabetes Mellitus Type 2chemistryAlbuminuriaORIGINAL ARTICLESbusinesschronic kidney diseaseKidney disease
researchProduct

Epinephrine Versus Norepinephrine for Cardiogenic Shock After Acute Myocardial Infarction

2018

IF 16.834 (2017); International audience; BACKGROUND Vasopressor agents could have certain specific effects in patients with cardiogenic shock (CS) after myocardial infarction, which may influence outcome. Although norepinephrine and epinephrine are currently the most commonly used agents, no randomized trial has compared their effects, and intervention data are lacking. OBJECTIVES The goal of this paper was to compare in a prospective, double-blind, multicenter, randomized study, the efficacy and safety of epinephrine and norepinephrine in patients with CS after acute myocardial infarction. METHODS The primary efficacy outcome was cardiac index evolution, and the primary safety outcome was…

MaleInotropeILL PATIENTSCardiac index030204 cardiovascular system & hematologyLACTATE0302 clinical medicine[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesSUPPORTTISSUE OXYGENATIONVasoconstrictor AgentsProspective StudiesMyocardial infarctionCardiogenic shockcardiogenic shockMiddle Aged3. Good healthEpinephrineCardiologyHEARTFemaleTRIALFranceCardiology and Cardiovascular Medicinemedicine.drugmedicine.medical_specialtyShock Cardiogenicacute myocardial infarctionvasopressornorepinephrineEXTRACORPOREAL MEMBRANE-OXYGENATIONNorepinephrine (medication)03 medical and health sciencesDouble-Blind MethodInternal medicineHeart rateMANAGEMENTmedicineHumansepinephrineAgedbusiness.industrySeptic shockMORTALITYSEPTIC SHOCKHemodynamics030208 emergency & critical care medicinemedicine.disease3121 General medicine internal medicine and other clinical medicinebusiness
researchProduct

The Heidelberg retina tomograph ancillary study to the European glaucoma prevention study: study design and baseline factors.

2013

Purpose: To describe the study design and baseline factors of the Heidelberg Retina Tomograph ancillary study within the EGPS. Furthermore, to examine the relationship between HRT optic disc topographic measurements and baseline demographic and ocular factors. Methods: Four hundred and eighty-nine ocular hypertensive participants were included. Each participant completed HRT imaging at least annually. The associations between HRT measurements and IOP, central corneal thickness (CCT), baseline photographic estimates of vertical CDR ratio (CDR), asymmetry between the two eyes in CDR ratio and baseline visual field indices were assessed using regression analysis. Results: Associations between …

MaleIntraocular pressureVisual acuitygenetic structuresOptic diskVisual AcuityOcular hypertensionGlaucomaOptic Nerve DiseasesMedicineHRT parameterCarbonic Anhydrase Inhibitorspattern standard deviationTomographySulfonamidesmedicine.diagnostic_testGeneral MedicineMiddle Agedmedicine.anatomical_structureResearch DesignOptic nerveFemalemedicine.symptomHumanOptic discmedicine.medical_specialtyCarbonic Anhydrase Inhibitorscanning laser ophthalmoscopyOptic DiskVisual FieldThiophenesSulfonamideOphthalmoscopyTonometry OcularOptic Nerve DiseaseDouble-Blind MethodThiopheneOphthalmologymental disordersHumansIntraocular Pressurebusiness.industryGlaucomamedicine.diseaseeye diseasesOphthalmoscopyOphthalmologyOcular Hypertensionsense organsVisual Fieldsbusinesscentral corneal thickneActa ophthalmologica
researchProduct

Randomized Trial of Brinzolamide/Brimonidine Versus Brinzolamide Plus Brimonidine for Open-Angle Glaucoma or Ocular Hypertension

2014

Introduction Fixed-combination intraocular pressure (IOP)—lowering medications simplify treatment regimens for patients requiring 2 ocular hypotensive agents to maintain sufficiently low IOP. The aim of this study was to evaluate the safety and efficacy of fixed-combination brinzolamide 1%/brimonidine 0.2% (BBFC) versus concomitant administration of brinzolamide 1% plus brimonidine 0.2% (BRINZ + BRIM) in patients with open-angle glaucoma or ocular hypertension. Methods This was a prospective, phase 3, multicenter, double-masked, 6-month trial. Patients who had insufficient IOP control with monotherapy or who were receiving 2 IOP-lowering medications were randomized 1:1 to receive twice-dail…

MaleIntraocular pressuremedicine.medical_specialtyConcomitantgenetic structuresIntraocular pressureBrinzolamideThiazinesOcular hypertensionGlaucomaOcular hypertensionlaw.inventionTonometry OcularRandomized controlled trialDouble-Blind MethodlawOphthalmologyQuinoxalinesConcomitant TherapyMedicineHumansPharmacology (medical)Fixed combinationCarbonic anhydrase inhibitorAntihypertensive AgentsOriginal ResearchAgedMedicine(all)Sulfonamidesbusiness.industryBrimonidineAlpha-2 agonistSimbrinza®GlaucomaGeneral MedicineMiddle Agedmedicine.diseaseeye diseasesDysgeusiaOphthalmologyDrug CombinationsTreatment OutcomeBrimonidine TartrateFemalesense organsmedicine.symptombusinessGlaucoma Open-Anglemedicine.drugAdvances in Therapy
researchProduct

Dexketoprofen/tramadol: randomised double-blind trial and confirmation of empirical theory of combination analgesics in acute pain

2015

Background Combination analgesics are effective in acute pain, and a theoretical framework predicts efficacy for combinations. The combination of dexketoprofen and tramadol is untested, but predicted to be highly effective. Methods This was a randomised, double-blind, double-dummy, parallel-group, placebo-controlled, single-dose trial in patients with moderate or severe pain following third molar extraction. There were ten treatment arms, including dexketoprofen trometamol (12.5 mg and 25 mg) and tramadol hydrochloride (37.5 mg and 75 mg), given as four different fixed combinations and single components, with ibuprofen 400 mg as active control as well as a placebo control. The study objecti…

MaleKetoprofenWisdom toothEmpirical Researchlaw.inventionPostoperative painDolor postoperatoriRandomized controlled triallawDose rangeAntiinflammatory agentsTromethamineTramadolRandomised controlled trialAnalgesicsAnti-Inflammatory Agents Non-SteroidalAgents antiinflamatorisQueixal del senyGeneral MedicineMiddle AgedIbuprofenAcute PainAnalgesics OpioidKetoprofenAnesthesiaTramadol HydrochlorideDrug Therapy CombinationFemaleTramadolResearch Articlemedicine.drugAdultAdolescentAnalgesicClinical NeurologyPlaceboOdontologiaYoung AdultAnalgèsicsDouble-Blind MethodThird molarPosologymedicineDexketoprofenHumansPain ManagementCombination analgesicsbusiness.industryDexketoprofenPosologiaAnesthesiology and Pain MedicineDentistryNeurology (clinical)Analgesiabusiness
researchProduct

Preoperative pain neuroscience education combined with knee joint mobilization for knee osteoarthritis : a randomized controlled trial

2017

Abstract: Objectives: This study aimed to first compare the effects of a preoperative treatment combining pain neuroscience education (PNE) with knee joint mobilization versus biomedical education with knee joint mobilization on central sensitization (CS) in patients with knee osteoarthritis, both before and after surgery. Second, we wanted to compare the effects of both interventions on knee pain, disability, and psychosocial variables. Materials and Methods: Forty-four patients with knee osteoarthritis were allocated to receive 4 sessions of either PNE combined with knee joint mobilization or biomedical education with knee joint mobilization before surgery. All participants completed self…

MaleKnee JointPsychological interventionOsteoarthritisKnee Jointlaw.inventionDisability Evaluation0302 clinical medicineRandomized controlled triallawOutcome Assessment Health CareMedicinephysical therapyPain MeasurementAged 80 and overMobilizationCatastrophizationMiddle AgedOsteoarthritis Kneemusculoskeletal systemPhobic DisordersManipulation OrthopedicFemalePain catastrophizingmedicine.symptomPsychosocialmusculoskeletal diseasesmedicine.medical_specialtyClinical NeurologyPaincentral sensitization syndromesknee osteoarthritisEducation03 medical and health sciencesDouble-Blind MethodPreoperative CareHumansPhysical Therapy ModalitiesAged030203 arthritis & rheumatologyAnalysis of Variancebusiness.industryNeurosciencesmedicine.diseaseAnesthesiology and Pain MedicineKnee painPhysical therapyNeurology (clinical)Human medicinebusinessNeuroscience030217 neurology & neurosurgeryThe clinical journal of pain
researchProduct

Rivaroxaban for thromboprophylaxis in acutely ill medical patients.

2013

International audience; BACKGROUND: The clinically appropriate duration of thromboprophylaxis in hospitalized patients with acute medical illnesses is unknown. In this multicenter, randomized, double-blind trial, we evaluated the efficacy and safety of oral rivaroxaban administered for an extended period, as compared with subcutaneous enoxaparin administered for a standard period, followed by placebo. METHODS: We randomly assigned patients 40 years of age or older who were hospitalized for an acute medical illness to receive subcutaneous enoxaparin, 40 mg once daily, for 10±4 days and oral placebo for 35±4 days or to receive subcutaneous placebo for 10±4 days and oral rivaroxaban, 10 mg onc…

MaleMESH: Factor Xa[SDV]Life Sciences [q-bio]Administration Oral030204 cardiovascular system & hematologylaw.inventionMESH: Venous Thromboembolismchemistry.chemical_compound0302 clinical medicineRivaroxabanRandomized controlled triallawMedicineMESH: Double-Blind Method030212 general & internal medicineMESH: AgedMESH: Middle AgedVenous ThromboembolismGeneral MedicineMiddle AgedMESH: Thiophenes3. Good healthAnesthesiaAcute DiseaseMESH: Administration OralMESH: Acute DiseaseFemaleMESH: Hemorrhagemedicine.drugAdultRandomizationMESH: EnoxaparinInjections SubcutaneousMorpholinesMESH: MorpholinesHemorrhageThiophenesMESH: AnticoagulantsMESH: Drug Administration SchedulePlaceboDrug Administration Schedule03 medical and health sciencesDouble-Blind MethodRivaroxaban venous thromboembolismHumansEnoxaparinAgedRivaroxabanMESH: Humansbusiness.industryMESH: Injections SubcutaneousAnticoagulantsMESH: AdultConfidence intervalMESH: MalechemistryBetrixabanRelative riskbusinessVenous thromboembolismMESH: FemaleFactor Xa Inhibitors
researchProduct

Effectiveness of a spray containing 1% malic acid in patients with xerostomia induced by graft-versus-host disease

2018

Background To evaluate the clinical effectiveness of a topical sialogogue spray (malic acid, 1%) in the treatment of xerostomia in patients with chronic Graft versus Host Disease (cGVHD). Material and Methods This study was designed as a randomized double-blind clinical study. Twenty-eight patients with cGVHD suffering from xerostomia were divided into 2 groups: the first group (14 patients) received a topical sialagogue spray containing malic acid 1% (SalivAktive®) whereas the second group (14 patients) received a placebo. Both groups received treatment for 2 weeks. Dry Mouth Questionnaire (DMQ) scores and unstimulated salivary flows rate were collected before and after treatment. Results …

MaleMalatesGraft vs Host DiseaseGastroenterologylaw.inventionchemistry.chemical_compound0302 clinical medicineRandomized controlled triallawSurveys and QuestionnairesMalic acidSialogogueMalic acid; Transplantation; XerostomiaOtorhinolaryngology2734 Pathology and Forensic MedicineMiddle AgedMedically compromised patients in Dentistry:CIENCIAS MÉDICAS [UNESCO]Treatment OutcomeUNESCO::CIENCIAS MÉDICASFemalemedicine.symptomOral SpraysSalivationAdultmedicine.medical_specialtyClinical effectivenessmalic acidPlaceboXerostomia03 medical and health sciencesDouble-Blind MethodInternal medicinemedicineHumansIn patientSalivaGeneral DentistryTransplantationbusiness.industryResearchXerostomia; malic acid; transplantation; Surgery; Otorhinolaryngology2734 Pathology and Forensic Medicine; Dentistry (all)030206 dentistrymedicine.diseaseDry mouthGraft-versus-host diseaseOtorhinolaryngologychemistryDentistry (all)SurgeryMalic acidbusinesstransplantation
researchProduct

Effects of a quercetin-rich onion skin extract on 24 h ambulatory blood pressure and endothelial function in overweight-to-obese patients with (pre-)…

2015

AbstractThe polyphenol quercetin may prevent CVD due to its antihypertensive and vasorelaxant properties. We investigated the effects of quercetin after regular intake on blood pressure (BP) in overweight-to-obese patients with pre-hypertension and stage I hypertension. In addition, the potential mechanisms responsible for the hypothesised effect of quercetin on BP were explored. Subjects (n 70) were randomised to receive 162 mg/d quercetin from onion skin extract powder or placebo in a double-blinded, placebo-controlled cross-over trial with 6-week treatment periods separated by a 6-week washout period. Before and after the intervention, ambulatory blood pressure (ABP) and office BP were m…

MaleMedicine (miscellaneous)Blood PressureBody Mass IndexPrehypertensionchemistry.chemical_compoundOnionsInsulinheterocyclic compoundsCross-Over StudiesNutrition and DieteticsbiologyFull PapersBlood Pressure Monitoring AmbulatoryMiddle AgedCardiovascular diseasesC-Reactive ProteinCholesterolTreatment OutcomeHypertensionBody CompositionQuercetinFemaleWaist CircumferenceQuercetinHuman and Clinical NutritionAdultmedicine.medical_specialtyMean arterial pressureAmbulatory blood pressurePlaceboPrehypertensionDouble-Blind MethodInternal medicinemedicineHumansObesityAntihypertensive AgentsTriglyceridesAgedPlant Extractsbusiness.industryBody WeightEndothelial functionAngiotensin-converting enzymeOverweightEndocrinologyBlood pressurechemistryDietary Supplementsbiology.proteinPatient ComplianceEndothelium VascularEnergy IntakeAsymmetric dimethylargininebusinessBiomarkersBritish Journal of Nutrition
researchProduct

Altilix

2019

The objective was to evaluate the effects of 6 months of supplementation with Altilix®, containing chlorogenic acid and its derivatives, and luteolin and its derivatives, on cardiovascular risk and hepatic markers in subjects with metabolic syndrome (MetS). A randomized, double-blind, placebo-controlled study was performed in 100 subjects with MetS with a follow-up period of 6 months; 50 subjects were randomized to Altilix® (26 men and 24 women, mean age 63 ± 8 years) and the other 50 to placebo (28 men and 22 women, mean age 63 ± 11 years). Anthropometric, cardiometabolic, and hepatic parameters were assessed at baseline and at the end of follow-up. Carotid intima-media thickness and endot…

MaleMetabolic Syndromecynaranon-alcoholic fatty liver diseaseMiddle AgedArticlecardiovascular diseasesdietary supplementsDouble-Blind MethodLivertype 2Risk Factorsdiabetes mellitusHumansFemaleChlorogenic AcidLuteolinBiomarkersAgedNutrients
researchProduct